Last reviewed · How we verify
Placebo to match aficamten
Placebo to match aficamten is a Small molecule drug developed by Cytokinetics. It is currently in Phase 3 development for Matching placebo for aficamten trials in hypertrophic cardiomyopathy. Also known as: Placebo.
This is an inert placebo formulation designed to match the physical and sensory characteristics of aficamten for blinded clinical trial purposes.
This is an inert placebo formulation designed to match the physical and sensory characteristics of aficamten for blinded clinical trial purposes. Used for Matching placebo for aficamten trials in hypertrophic cardiomyopathy.
At a glance
| Generic name | Placebo to match aficamten |
|---|---|
| Also known as | Placebo |
| Sponsor | Cytokinetics |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo matching is used in randomized controlled trials to maintain blinding and reduce bias. This placebo is formulated to be indistinguishable from aficamten (a cardiac myosin inhibitor) in appearance, taste, and administration to ensure trial integrity and allow for valid comparison of aficamten's true therapeutic effects against control.
Approved indications
- Matching placebo for aficamten trials in hypertrophic cardiomyopathy
Common side effects
Key clinical trials
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (PHASE3)
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (PHASE3)
- Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match aficamten CI brief — competitive landscape report
- Placebo to match aficamten updates RSS · CI watch RSS
- Cytokinetics portfolio CI
Frequently asked questions about Placebo to match aficamten
What is Placebo to match aficamten?
How does Placebo to match aficamten work?
What is Placebo to match aficamten used for?
Who makes Placebo to match aficamten?
Is Placebo to match aficamten also known as anything else?
What development phase is Placebo to match aficamten in?
Related
- Manufacturer: Cytokinetics — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Matching placebo for aficamten trials in hypertrophic cardiomyopathy
- Also known as: Placebo
- Compare: Placebo to match aficamten vs similar drugs
- Pricing: Placebo to match aficamten cost, discount & access